Answers are grounded in this paper and cite their sources.
Introduction Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive condition. Effective treatment is important as patients are at risk for severe and potentially fatal acute pancreatitis. We review recent developments in pharmacologic treatment for FCS, namely biological inhibitors of apolipoprotein (apo) C-III and angiopoietin-like protein 3 (ANGPTL3).
No takes yet. Share an insight, caveat, or question.
Spagnuolo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: